QNRX QUOIN PHARMACEUTICALS LTD US FDA Inspections 8-K Filing 2023 - FDA Clearance for Clinical Trial Amendments Quoin Pharmaceuticals received clearance from the FDA to implement protocol amendments to its ongoing clinical trials for QRX003, a potential treatment for Netherton Syndrome.Get access to all SEC 8-K filings of the QUOIN PHARMACEUTICALS LTD